Four well-known companies—Pfizer, UPS, Kraft Heinz, and Ford—offer dividend yields above 5%, but their earnings, cash flow, and debt levels raise doubts about the sustainability of these payouts. Pfizer and UPS pay dividends exceeding their GAAP earnings, relying on adjusted earnings and cost savings to maintain payouts. Kraft Heinz faces shrinking sales and earnings, while Ford struggles with heavy debt and losses, especially in its EV segment. Investors should be cautious, as dividend cuts could reduce income and share prices, making high yields alone a risky investment signal.
Pfizer and Kraft Heinz, two stocks mentioned for dividend concerns, currently show dividend yields of 6.18% and 7.12% on Pluang. Pfizer trades at USD 27.77 with a slight 0.18% decline, while Kraft Heinz is priced at USD 22.44, also down 0.18%. These figures are as of Oct 09, 2026 18:41 WIB, reflecting current market sentiment on Pluang.
Pfizer's dividend yield has risen above 6%, notably higher than peers, due to a share price decline despite steady dividends. While the company maintains a strong earnings buffer and CEO Albert Bourla has assured the dividend will hold, free cash flo...
Moderna's stock rose 5% following its addition to the NASDAQ 100, driven by automatic fund buying linked to the index inclusion. This marks a shift from its COVID-19 vaccine identity to a growth biotech with a promising oncology pipeline, highlighted...
Cantor Fitzgerald increased price targets for four major pharmaceutical companies: Eli Lilly, AbbVie, Merck, and Pfizer, while maintaining their current ratings. Eli Lilly and AbbVie received Overweight ratings with higher targets, reflecting stronge...
Pfizer expects its stronger non-COVID business to more than offset lower revenue from COVID-related products, though full-year revenue guidance still indicates a decline. The company plans to achieve $2.7 billion in cost savings through 2029, which c...
Pfizer offers a dividend yield of 6.24%, much higher than Johnson & Johnson's 2.07%, but Pfizer's payout is frozen and not fully covered by free cash flow, with rising debt and a recent $4.3 billion write-down signaling risk. Johnson & Johnson, despi...
